Clinical Research Directory
Browse clinical research sites, groups, and studies.
ctDNA in HER2+ EBC Neoadjuvant Treatment
Sponsor: Shanghai Jiao Tong University School of Medicine
Summary
This study is a randomized, open-label, multicenter clinical study for patients with early or locally advanced (T≥2cm, N0-3, M0) HER2-positive breast cancer, aiming to compare the peripheral blood ctDNA clearance of neoadjuvant pyrotinib + trastuzumab + docetaxel and pertuzumab + trastuzumab + docetaxel for one course and to evaluate the therapeutic effectiveness of four courses of neoadjuvant therapy
Official title: A Randomized, Multicenter, Open-label Clinical Study Using Peripheral Blood Circulating Tumor DNA to Evaluate the Efficacy of Preoperative Treatment With Pyrotinib + Trastuzumab + Docetaxel Versus Pertuzumab + Trastuzumab + Docetaxel in Early or Locally Advanced HER2-positive Breast Cancer
Key Details
Gender
FEMALE
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2024-02-01
Completion Date
2026-12-31
Last Updated
2026-03-24
Healthy Volunteers
No
Conditions
Interventions
pyrotinib
pyrotinib 320mg p.o. qd
pertuzumab
pertuzumab ivgtt q3w, 840mg for initiation, 420mg for maintenance
trastuzumab
trastuzumab ivgtt q3w, 8mg/kg for initiation, 6mg/kg for maintenance
docetaxel
docetaxel ivgtt q3w, 80-100mg/m2
Locations (1)
Ruijin Hospital
Shanghai, China